002007 Hualan Biological Engineering, Inc.
- 17.79
- -0.24-1.33%
Hualan Biological Engineering, Inc. News
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research report released by Huaxin Securities, with the support and attention of domestic policies, the planning of plasma stations such as "14th Five-Year Plan" is gradually landing, and the construction of plasma stations is accelerating. The scale of plasma collection in China will continue to increase. In 2023, the plasma collection volume will exceed 12,079 tons, an increase of more than 18.6% compared to 2022. Blood products are essential medicines and the entire industry is licensed businesses, which determines their natural high policy barrier characteristics. Plasma collection scale, plasma comprehensive utilization rate, and plasma profit-making ability are the core factors. Plasma collection scale directly determines the size of enterprises, and the number of existing varieties and research products are used to determine the plasma comprehensive utilization rate and plasma profit-making ability.
Hualan Biological Reduce Quadrivalent Influenza Vaccine Prices
Hualan Biological (SHE:002007) adjusted the prices of quadrivalent influenza vaccine products starting from June 5, according to a Wednesday filing on the Shenzhen bourse. The company expects a negati
Hualan Biological Engineering, Inc. (002007.SZ): 10 shares and 3 yuan per share for equity distribution in 2023, with a registration date of June 13th.
On June 5, Gelunhui reported that Hualan Biological Engineering, Inc. (002007.SZ) announced its annual equity distribution plan for 2023: based on the company's existing total share capital of 1,828,780,926 shares, it will distribute RMB 3 in cash (tax included) for every 10 shares to all shareholders. The equity distribution record date for this distribution is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Express News | Midday announcement: Qingdao East Steel Tower Stock won the bid for a 108 million yuan project.
Hualan Biological Engineering, Inc. (002007.SZ): Its subsidiary adjusts the price of quadrivalent influenza vaccine products.
On June 5th, Gelon Hui announced that in order to improve the accessibility of influenza vaccines, enhance the company's product market competitiveness and market share, reduce the economic burden on the people and the government, and fulfill corporate social responsibility, combined with the current market situation, Hualan Biological Engineering, Inc., a holding subsidiary of Hualan Biological Technology Co., Ltd., after careful research and demonstration, decided to adjust the prices of quadrivalent influenza vaccine products from June 5th, 2024: 1. Quadrivalent influenza split virus vaccine (adult formulation, prefilled 0.5ml/syringe) adjusted to 88 yuan/syringe; 2. Quadrivalent influenza virus vaccine
Hualan Biological Engineering's Blood Centers Get License to Operate
Two of Hualan Biological Engineering's (SHE:002007) blood collecting centers are now allowed to operate after receiving licenses from the health commission of China's Henan Province, the company said
A subsidiary of Hualan Biology (002007.SZ) obtained a single plasma collection license
Zhitong Finance App News, Hualan Biology (002007.SZ) announced that on May 15, 2024, Hualan Biotech Qixian Single Plasma Collection Station and Hualan Biotech Xiangcheng Single Plasma Collection Station, which are affiliated with the company, obtained the “Single Plasma Collection License” issued by the Henan Provincial Health Commission.
Hualan Biology (002007): Blood products business is steady awaiting the release of influenza vaccine
Incident: The company released its 2024 quarterly report. In the first quarter of 2024, the company achieved operating income of 787 million yuan, a year-on-year decrease of 10.60%; achieved net profit to mother of 262 million yuan, a year-on-year decrease of 25.56%; in fact
Hualan Biology (002007): The Q1 blood products business remains steady and we expect the influenza vaccine to be released
Core view On April 25, the company released its 2024 quarterly report. The year-on-year decline in performance was mainly due to a high sales base for influenza vaccines, and the blood products business maintained steady growth. In terms of blood products, it is expected that as the amount of pulp collected continues to increase, it will be superimposed
Hualan Biotech (002007): 1Q24 revenue was affected by seasonal fluctuations in vaccine, and the growth of blood products was relatively stable
1Q24 net profit is in line with our expectations. The company announced 1Q24 results: revenue of 787 million yuan, down 10.6% year on year; net profit to mother 262 million yuan, down 25.56% year on year, corresponding to earnings per share of 0.14
Hualan Biology (002007): Stable blood products and vaccines return to normal
1Q24 non-profit deduction fell 20% The company announced 1Q24 revenue, return to mother, and deducted non-net profit of 7.9, 260, and 220 million yuan, a year-on-year decline of 11%, 26%, and 20%, mainly due to vaccine companies returning to normal rhythm in the first quarter
China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2
China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2) the first batch of influenza vaccines was issued in April. (Mainichi Keizai Shimbun)
Express News | Hualan Biotech: Net profit from mother in the first quarter was 262 million yuan, down 25.56% year on year
Hualan Biology (002007): The growth rate of pulp collection is impressive, and the blood products business is expected to accelerate
Incident: The company announced its 2023 annual report, achieving operating income of 5.342 billion yuan (+18.26%), net profit to mother of 1,482 billion yuan (+37.66%), and net profit of non-return to mother of 1,267 billion yuan (+
Hualan Biology (002007.SZ): Intravenous human immunoglobulin (IVIG) (10%) is in phase III clinical trials
Gelonghui, April 15 | Hualan Biology (002007.SZ) said on the investor interactive platform that intravenous human immunoglobulin (IVIG) (10%) developed by the company is in phase III clinical trials.
Hualan Biology (002007): Continued increase in the company's pulp collection is expected to drive the accelerated growth of the blood products business
It is expected to maintain a dividend rate of no less than 30% in the next three years: according to the company's annual report, the company achieved operating income of 5.341 billion yuan in 2023, an increase of 18% over the previous year; realized net profit to mother of 1,482 billion yuan, an increase of 38% over the previous year.
Hualan Biotech (002007): Performance is in line with expectations, accelerated pulp collection lays the foundation for future growth
Core idea: The company releases its 2023 annual report. In 2023, the company achieved revenue of 5.342 billion yuan (+18.26%, the following are year-on-year ratios), net profit to mother of 1,482 billion yuan (+37.66%), deductions
Hualan Biotech (002007): Performance is in line with expectations, slurry volume growth exceeds expectations
Incident: The company released its 2023 report. During the period, it achieved revenue of 5.34 billion yuan, +18.3% year-on-year, and realized net profit of 1.48 billion yuan, +37.7% year-on-year, net profit of 1.27 billion yuan after deducting non-return to mother net profit of 1.27 billion yuan, year-on-year
Hualan Biology (002007) Company Brief Review Report: Increased pulp collection volume can be expected to increase significantly
The profit side performed brilliantly. In 2023, the company achieved operating income of 5.342 billion yuan (+18.26%), net profit attributable to mother of 1,482 billion yuan (+37.66%), and net profit without return to mother of 1,267 billion yuan (+41.
Hualan Biotech (002007): Blood products+vaccine dual-wheel drive will positively return shareholders in the next three years
Core view On March 29, the company released its 2023 annual report, and the performance was in line with expectations. In 2023, the company's overall performance achieved good growth. Among them, the blood products business maintained steady development, and the amount of pulp collected increased rapidly; low base+connection
Analysis
Price Target
No Data
